Your session is about to expire
← Back to Search
Dopamine Agonist
Quinagolide 360 µg for Endometriosis (RAQUEL Trial)
Phase 2
Waitlist Available
Research Sponsored by Ferring Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Pre-menopausal females aged ≥18 years at time of signing informed consent(s).
Body mass index (BMI) of 18-42 kg/m2 (both inclusive) at screening.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline and at menstrual cycle 4 (around 4 months)
Awards & highlights
RAQUEL Trial Summary
This trial looks at whether quinagolide, given as a vaginal ring, can reduce pain from endometriosis.
Eligible Conditions
- Endometriosis
RAQUEL Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRAQUEL Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at baseline and at menstrual cycle 4 (around 4 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline and at menstrual cycle 4 (around 4 months)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
Changes in Bone Turnover Markers, Determined by Bone Formation Marker Serum Procollagen Type I N Propeptide (s-PINP)
Changes in Bone Turnover Markers, Determined by Bone Resorption Marker Serum C-terminal Crosslinking Telopeptide of Type 1 Collagen (s-CTx)
Changes in Circulating Levels of Clinical Chemistry Parameters: Alanine Aminotransferase
+75 moreSide effects data
From 2022 Phase 2 trial • 22 Patients • NCT0369240333%
Foot fracture
33%
Major depression
33%
Uterine disorder
33%
Corona virus infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Quinagolide 720 µg - Part B
Quinagolide 1080 µg - Part A
Quinagolide 360 µg - Part B
Quinagolide 360 µg - Part A
Placebo - Part A
Quinagolide 1080 µg - Part B
Quinagolide 720 µg - Part A
RAQUEL Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Quinagolide 720 µgExperimental Treatment1 Intervention
Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
Group II: Quinagolide 360 µgExperimental Treatment1 Intervention
Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
Group III: Quinagolide 1080 µgExperimental Treatment1 Intervention
Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
Group IV: PlaceboPlacebo Group1 Intervention
Vaginal ring containing matching placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Quinagolide 360 µg
2018
Completed Phase 2
~30
Quinagolide 1080 µg
2019
Completed Phase 2
~90
Quinagolide 720 µg
2018
Completed Phase 2
~30
Find a Location
Who is running the clinical trial?
Ferring PharmaceuticalsLead Sponsor
313 Previous Clinical Trials
440,836 Total Patients Enrolled
2 Trials studying Endometriosis
97 Patients Enrolled for Endometriosis
Global Clinical ComplianceStudy DirectorFerring Pharmaceuticals
62 Previous Clinical Trials
357,373 Total Patients Enrolled
1 Trials studying Endometriosis
67 Patients Enrolled for Endometriosis
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What site did they apply to?
Medical Center for Clinical Research
What portion of applicants met pre-screening criteria?
Met criteria
What questions have other patients asked about this trial?
How many visits to the centre do you make?
PatientReceived 1 prior treatment
Why did patients apply to this trial?
I have had laparoscopic surgeries and the endometriosis always comes back. I’m in pain. I do not want to use hormonal suppressants as they make me feel very down. I want to help others with endometriosis.
PatientReceived 1 prior treatment
Share this study with friends
Copy Link
Messenger